Treatment for Brain Fog After Chemo, Cognitive Decline Research

• In the largest review conducted to date (143 studies, 5,800 participants), TMS produced large improvements in cognition versus sham stimulation in patients with mild cognitive impairment and early Alzheimer's, with virtually zero serious side effects.
• A year-long clinical trial showed precuneus-targeted TMS slowed Alzheimer's progression by 44%, outpacing the newest FDA-approved drugs while avoiding their most serious side effects.
• For cancer survivors with chemo brain, the first published TMS case produced a large improvement in learning ability, moving performance from severely impaired to low-normal.
• Accelerated TMS protocols now compress weeks of treatment into just 3–5 days, using brain imaging to personalize every session to the patient's neural architecture.
• Unlike anti-amyloid antibody drugs, which carry risks of brain swelling in up to 24% of patients, TMS has recorded zero treatment-related deaths across the published literature.

It starts small. A word that used to come easily now hovers just out of reach. You walk into a room and forget why. You read the same paragraph three times and it still doesn't stick.

For some people, this is the slow creep of age-related cognitive decline. For others, it arrived suddenly after chemotherapy. Either way, the experience is the same: you know your brain isn't working the way it used to, and nobody seems to take it seriously.

If you've been told "it's just aging,” “the chemo fog will lift on its own,” you’re not imagining things. These cognitive changes are real, measurable, and rooted in specific biological disruptions happening in your brain right now — white matter damage, chronic neuroinflammation, and neural connections going quiet when they should be firing.

And for the first time, there's a technology that can directly target and address those disruptions — without drugs, without surgery, and without the side effects that have plagued every pharmaceutical attempt to fix this problem.That technology is Transcranial Magnetic Stimulation (TMS), and the data from 2024–2026 has fundamentally changed how we think about treating cognitive decline.

Table of Contents

• Why 2026 is the inflection point for TMS
• The evidence: what 5,800 patients tell us about TMS and memory
• 44% slower decline: the year-long precuneus TMS trial
• Accelerated TMS protocols: days instead of weeks
• fMRI-guided TMS: precision targeting for the individual brain
• TMS for chemo brain: the frontier cancer survivors have been waiting for
• How TMS actually works
• Is TMS safe for seniors and cancer survivors?
• TMS vs. FDA-approved Alzheimer's drugs
• What treatment looks like at Cognitive FX
• A note on menopause brain fog
• Is TMS right for you?
• Frequently asked questions

Note: Cognitive FX offers fMRI-guided accelerated TMS — a five-day, in-house protocol delivering approximately 79% remission rates for treatment-resistant depression in clinical research. To find out whether you're a good fit, take our TMS quiz or sign up for a consultation. Individual results vary.

TMS for Brain Fog and Cognitive Decline: Why 2026 Is the Inflection Point

For decades, the medical community's approach to memory loss followed the same playbook: diagnose the decline, prescribe a cholinesterase inhibitor, and hope for the best. For mild cognitive impairment, no treatment was approved. For chemo brain, there was nothing — patients were sent home with suggestions to 'try crossword puzzles.'

That era is ending.

The inflection point arrived not from a single breakthrough but from a critical mass of clinical evidence that has accumulated since 2020. We are no longer asking whether TMS works for memory and cognition. We are asking how well, and for whom, and which protocol delivers the strongest results.

Here is why that matters:

The newest FDA-approved Alzheimer's drugs, lecanemab and donanemab, slow decline by 27–36% but carry serious risks: brain swelling occurs in up to 24% of patients, brain microbleeds in up to 31%, and several treatment-related deaths have been reported. Annual drug costs exceed $26,000, and total treatment costs including mandatory MRI monitoring, amyloid PET scans, and genetic testing are substantially higher. These drugs don't work for MCI, chemo brain, or the millions whose cognitive decline doesn't involve amyloid plaques.Meanwhile, a different category of medicine has been quietly compiling an evidence base that no drug can match.

The Evidence: What 5,800 Patients Tell Us About TMS and Memory

TMS for Mild Cognitive Impairment and Early Alzheimer's Disease

The strongest data comes from the population where the clinical need is greatest: older adults experiencing the early stages of cognitive decline.

The largest systematic review to date analyzed 143 studies involving 5,800 participants, including 94 randomized controlled trials, and found that TMS significantly outperformed sham stimulation on every major cognitive assessment. The improvements were large across every measure — general cognitive testing, screening assessments, and the specific test used to track Alzheimer's disease progression all showed clear benefits.

For comparison, cholinesterase inhibitors — the longstanding standard of care for Alzheimer's — produce cognitive improvements roughly 3 to 9 times smaller in clinical trials, with a fraction of TMS's safety profile.

44% Slower Decline: The Koch Lab's Year-Long Breakthrough

A 52-week randomized trial in 48 patients with mild-to-moderate Alzheimer's disease found that active TMS targeting the precuneus slowed disease progression by 44% compared to sham stimulation. The precuneus is a hub of the brain's default mode network and one of the earliest areas disrupted in Alzheimer's. The trial built on an earlier sham-controlled precuneus-targeting study from the same research group.

After one year, patients receiving active TMS declined by less than half as much as sham patients on the Clinical Dementia Rating scale — a difference that translated to 44% slower disease progression.

To appreciate how significant this is: lecanemab (Leqembi) slowed decline by 27% over 18 months in its pivotal trial, and donanemab (Kisunla) achieved 35% in its own pivotal trial. TMS, without a single systemic side effect, outperformed both.

The benefits extended beyond a single test score. On measures of daily functioning, the TMS group barely declined over the year while the sham group's functioning worsened significantly. Cognition, behavioral symptoms, and general cognitive screening all favored the active treatment group.

The SinaptiStim system received FDA Breakthrough Device Designation, and its Phase 3 pivotal trial is now underway. If successful, it would become the first FDA-cleared device for treating cognitive decline in Alzheimer's disease.

Accelerated TMS Protocols for Cognitive Decline: Days Instead of Weeks

One of the most practical barriers to TMS treatment has been time. Traditional protocols require daily sessions over 4–6 weeks, a schedule that can be difficult for patients with cognitive impairment and their caregivers. Accelerated protocols are solving that problem.

A Phase I trial of accelerated iTBS for amnestic MCI delivered 8 sessions per day over 3 days (14,400 total pulses). Patients showed large cognitive improvements, 95% of elderly participants completed the full protocol, and no adverse events were reported. A follow-up study confirmed that these cognitive improvements corresponded to measurable changes in brain connectivity on fMRI, confirming the treatment was rewiring neural circuits rather than producing a placebo effect.

The National Institute on Aging is funding a Phase II dose-finding trial now underway. This trial will determine the optimal number of treatment days and sessions needed to produce lasting cognitive improvement in MCI.

fMRI-Guided TMS: Precision Targeting for the Individual Brain

Perhaps the most exciting development is the shift from one-size-fits-all brain targeting to individualized, image-guided protocols.

Every brain is different. The exact location of critical neural hubs varies by several centimeters between individuals. Standard TMS protocols use anatomical landmarks to estimate where to place the coil, but this approach can miss the optimal target entirely.

A pioneering technique used each patient's resting-state fMRI to identify the specific spot on the brain's surface with the strongest connection to memory circuits deep in the temporal lobe.

In a follow-up study of cognitively normal older adults, this fMRI-guided approach actually reversed age-related memory decline, bringing performance back to the level of young adults.

The first randomized trial of fully personalized fMRI-guided TMS in amyloid-confirmed Alzheimer's disease found the personalized approach substantially improved cognition compared to sham, with fMRI confirming increased hippocampal connectivity that correlated with cognitive gains.

Clinical data from the Acacia Clinic across 195 patients found that fMRI-guided targeting produced response rates 2.3 times higher than standard anatomical targeting (77.5% vs. 62%).

TMS for Chemo Brain: The Frontier That Cancer Survivors Have Been Waiting For

First Published TMS Result for Chemo Brain

Chemotherapy saves lives. It also damages brains. Up to 75% of cancer patients experience cognitive problems during or shortly after chemotherapy, and a meta-analysis placed the incidence of persistent "chemo brain" at nearly 40% among breast cancer survivors alone.

With an estimated 18 million cancer survivors in the United States, millions are living with cognitive impairment that affects their ability to work, parent, manage finances, and live independently — and for which there is no FDA-approved treatment.

Chemo brain is not "in your head." Neuroimaging studies have documented the physical damage: reduced white matter integrity in the prefrontal cortex, chronic microglial activation (brain inflammation), depleted BDNF (the protein responsible for maintaining neural connections), and disrupted functional connectivity between brain regions critical for memory and executive function. Chemotherapy drugs, particularly agents like methotrexate, 5-fluorouracil, and doxorubicin, are directly toxic to the neural support cells (oligodendrocytes) that maintain the insulation around nerve fibers.

These are the same pathways that TMS is designed to restore.

The Case That Changed the Conversation

The published clinical evidence for TMS in chemo brain currently rests on a single case from the University of Arizona, but it is a powerful one. A 58-year-old breast cancer survivor with seven years of cognitive impairment received 10 sessions of MRI-navigated iTBS and showed a 1.53 standard deviation improvement in learning, with fMRI-confirmed increases in functional connectivity.

On a standard test of learning and memory, her performance moved from severely impaired (bottom 1% of the population) to the low-normal range — an improvement of more than 1.5 standard deviations, a magnitude of change rarely seen in cognitive rehabilitation.

Resting-state fMRI confirmed increased functional connectivity between the stimulation site and six other brain regions, suggesting the treatment had reactivated dormant neural circuits. The patient later returned to work at a higher level after years of cognitive difficulties limiting her career.

This case emerged from the only registered clinical trial of TMS for chemo brain, a Phase I pilot. No results have been formally published beyond this single patient, and no additional TMS-specific chemo brain trials have been registered as of early 2026.

Why TMS Should Work for Chemo Brain: The Mechanistic Case

Although the clinical data is early-stage, the biological rationale for TMS in chemotherapy-related cognitive impairment is among the strongest of any potential application. The overlap between what chemotherapy damages and what TMS repairs is nearly complete:

Chemotherapy triggers neuroinflammation. Pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) surge during and after treatment, activating microglia and damaging the blood-brain barrier. A systematic review demonstrated that rTMS produces a significant decrease in TNF-alpha and a significant increase in BDNF, directly counteracting the two most critical molecular disruptions in chemo brain. TMS upregulates the same BDNF-TrkB pathway that chemotherapy agents like methotrexate suppress, promoting the neurogenesis and synaptic remodeling needed to repair these circuits.

Chemotherapy damages prefrontal white matter. Agents like methotrexate specifically reduce BDNF levels and white matter TrkB signaling in the frontal cortex. TMS upregulates the same BDNF-TrkB pathway, promoting the neurogenesis, dendritic spine formation, and synaptic remodeling needed to repair these circuits.

The prefrontal cortex is the region most vulnerable to chemo brain, and the region where TMS has the most evidence. The left DLPFC controls working memory, attention, executive function, and multitasking. It is the FDA-cleared TMS target for depression. PET and fMRI studies document altered prefrontal activation in chemotherapy-treated patients years after treatment completion. Stimulating this hub can modulate widespread networks and restore connectivity degraded by chemotherapy.

How TMS Actually Works: Waking Up Dormant Brain Connections

To understand why TMS works across such different conditions, from age-related MCI to post-chemotherapy cognitive impairment, you need to understand what these conditions share at the cellular level: weakened neural connections, reduced brain plasticity, and chronic low-grade inflammation.

TMS addresses all three.

A TMS coil generates focused magnetic pulses that pass painlessly through the skull and induce electrical currents in targeted brain tissue. Unlike medications, which flood the entire body and brain, TMS delivers its effects to a specific neural circuit with millimeter precision.

When delivered at high frequencies (typically 10-20 Hz) or in specific burst patterns (like intermittent theta burst stimulation), TMS induces a process called long-term potentiation, the same mechanism your brain uses to form memories naturally. Think of it as waking up dormant connections: neurons that had stopped communicating begin firing together again, and through repeated stimulation, those pathways strengthen and stabilize.

The downstream effects are measurable and wide-ranging:

• Increased BDNF production, the brain's primary growth factor for maintaining and building neural connections
• Dopamine and acetylcholine release in circuits critical for attention, memory, and motivation
• Reduced neuroinflammation, shifting activated immune cells in the brain from a damaging (M1) to a protective (M2) state
• Improved cerebral blood flow, particularly to the hippocampus and medial temporal regions where memories are formed
• Reorganized neural networks, strengthening connections within the default mode network and frontoparietal network while reducing pathological hyperactivation

These aren't theoretical mechanisms — they have been documented in human neuroimaging studies, PET scans, blood biomarker measurements, and animal models.

Is TMS Safe for Seniors and Cancer Survivors?

This is the question that matters most, and the answer is the strongest argument in TMS's favor.

Across the entire published literature on TMS for cognitive decline, encompassing 143 studies and 5,800 participants, the safety data showed zero treatment-related deaths and zero cases of ARIA.

• Zero treatment-related deaths
• Zero cases of ARIA (the brain swelling that occurs in up to 24% of patients on anti-amyloid drugs)
• Only 4 seizure events, with 3 deemed unrelated to TMS
• No systemic side effects (no gastrointestinal effects, no liver effects, no drug interactions)

The most common side effects are mild and transient: temporary scalp discomfort at the stimulation site and occasional headache that resolves within hours.

For elderly patients, systematic reviews of TMS in adults over 60 have documented low rates of serious adverse events and no seizures. In the accelerated MCI trial referenced above, 95% of elderly participants completed the full protocol (8 sessions per day for 3 days), with no adverse findings on post-treatment MRI.

For cancer survivors, recent scoping reviews of TMS studies in oncology patients have reported no serious adverse events. TMS is particularly attractive for this population because it avoids systemic absorption entirely, meaning no interactions with endocrine therapy, immunotherapy, or other cancer medications. There are no cancer-specific contraindications beyond standard TMS screening.

Compare this to the current pharmaceutical landscape:

While TMS is FDA-cleared for depression and OCD, cognitive protocols are used off-label at academic centers and specialized clinics based on the clinical evidence accumulated since 2020. Sinaptica Therapeutics' Phase 3 pivotal trial, now enrolling patients, may result in the first FDA clearance specifically for cognitive decline within the coming years.

What Treatment Looks Like: From Brain Scan to Cognitive Recovery

Cognitive FX offers fMRI-guided accelerated TMS, an in-house program built on the same evidence base described in this article. The protocol condenses TMS treatment into five days, delivering 10 iTBS sessions per day (50 total sessions, approximately 90,000 pulses over the week). Each session lasts about 10 to 12 minutes. Cost ranges from $7,000 to $12,000 depending on the treatment package.

Step 1: Functional brain assessment. Before treatment begins, a comprehensive evaluation includes CFX's proprietary functional NeuroCognitive Imaging (fNCI) scan, neuropsychological testing, and a thorough clinical history. This produces a detailed map of which brain regions are underperforming and which neural networks need support.

Step 2: Personalized protocol design. Based on the brain imaging results, CFX's neuroscientist and physician design a treatment protocol tailored to the patient's specific pattern of dysfunction. The coil is positioned over the dorsolateral prefrontal cortex — the standard TMS target for depression and executive function — with placement guided by the fNCI results and personalized E-field coil orientation.

Step 3: Treatment sessions. Over five days, patients receive 10 sessions of intermittent theta burst stimulation per day. Each session takes about 10 to 12 minutes. Patients sit comfortably in a chair while the TMS coil is positioned on the head. Most describe the sensation as a light tapping on the scalp. Cognitive behavioral therapy is incorporated alongside TMS to support sustained improvement.

Step 4: Monitoring and follow-up. CFX tracks cognitive outcomes throughout treatment using validated neuropsychological measures. The care team follows up after treatment to monitor progress and address ongoing needs.

Who is a good fit: Adults between 18 and 65 with treatment-resistant depression, and — based on emerging evidence — patients with cognitive difficulties that haven't responded to standard care. Patients considering TMS for MCI, chemo brain, or Long COVID cognitive symptoms should discuss their specific situation with CFX's clinical team.

Who should wait: Patients under 18 or over 65, those with a history of seizures, those actively suicidal and in need of crisis care, and those with metallic implants near the treatment site (cochlear implants, aneurysm clips, internal pulse generators).

The Fog Lifts: What Patients Can Expect

The clinical data paints a clear picture of what cognitive improvement looks like after TMS treatment.

For patients with MCI and early cognitive decline, the meta-analytic evidence shows improvements in general cognition, disease-specific measures, daily functioning, and behavioral symptoms. The 52-week precuneus TMS trial demonstrated that treated patients remained nearly stable on global cognitive measures while untreated patients continued to decline.

For chemo brain, the available evidence suggests improvements in learning efficiency, memory recall, and the functional connectivity between brain regions responsible for attention and executive function. The first published case demonstrated that these improvements can translate into real-world functioning gains months after treatment.

What most patients report is not a sudden dramatic change, but a gradual return of cognitive clarity: words come more easily, reading comprehension improves, multitasking becomes possible again, and the constant mental fog begins to lift.

A Note on Menopause Brain Fog

This article focused on MCI and chemo brain, but menopause-related cognitive decline is the largest research gap in the TMS-for-cognition field. Roughly 60% of women experience cognitive difficulties during the menopausal transition, yet no clinical studies have tested TMS for this indication.

The biology suggests TMS should work: the DLPFC is dense with estrogen receptors, and declining estrogen directly reduces prefrontal function. Research has shown that cortical excitability correlates with cognitive performance in women, pointing to sex-specific mechanisms that TMS could leverage.The biology is promising, but until clinical trials specifically test TMS for menopause-related cognitive symptoms, patients weighing this option should discuss it carefully with their care team.

Is TMS Right for You?

TMS for cognitive decline may be appropriate if you:

• Have been diagnosed with mild cognitive impairment or early-stage Alzheimer's disease
• Are experiencing persistent cognitive difficulties following chemotherapy ("chemo brain")
• Notice progressive memory loss, difficulty concentrating, or brain fog that interferes with daily life
• Have not found relief from current medications or have experienced intolerable side effects
• Are looking for a non-invasive, drug-free treatment option

TMS is generally not appropriate for individuals with metallic implants near the treatment area (cochlear implants, aneurysm clips, or deep brain stimulators), a history of seizures or epilepsy, or those taking medications that significantly lower the seizure threshold.

If you're experiencing cognitive difficulties from MCI, chemo brain, or persistent brain fog and haven't found answers, our fMRI-guided accelerated TMS program may be worth exploring. Take our short TMS quiz, sign up for a consultation, or call 385-334-6093.

Further Reading

• Patient Guide to TMS for Treatment-Resistant Depression
• Post-COVID Brain Fog Treatment: Evidence-Based Options That Actually Work
• Cognitive Problems After TIA: Memory Loss, Brain Fog & Treatment Plans
• How to Recover from Memory Loss After a Head Injury
• Is TMS Safe? Answers for Patients Considering TMS Therapy

References

1. Aghamoosa S, Lopez J, Rbeiz K, Fleischmann HH, Horn O, Madden K, et al. A phase I trial of accelerated intermittent theta burst rTMS for amnestic MCI. Journal of Neurology, Neurosurgery & Psychiatry.2024;95(11):1036-1045. https://doi.org/10.1136/jnnp-2023-332680
2. Aghamoosa S, Nolin SA, Benitez A. Accelerated iTBS-Induced Changes in Resting-State Functional Connectivity Correspond with Cognitive Improvement in Amnestic MCI. Brain Stimulation. 2025;18(3):957-964. https://doi.org/10.1016/j.brs.2025.04.012
3. Asadizeidabadi A, Hosseini S, Pyatkov A. Effects of Repetitive Transcranial Magnetic Stimulation on Tumor Necrosis Factor Alpha in Neuropsychological Disorders: A Systematic Review and Meta-Analysis. Brain and Behavior. 2025;15(2):e70329. https://doi.org/10.1002/brb3.70329
4. Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging. 2020;86:1-10. https://doi.org/10.1016/j.neurobiolaging.2019.08.020
5. Drumond Marra HL, Myczkowski ML, Maia Memoria C, et al. Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. Behavioural Neurology. 2015;2015:287843. https://doi.org/10.1155/2015/287843
6. El Haj M, et al. The chemobrain in breast cancer patients: a systematic review and meta-analysis. Scientific Reports. 2025;15:35765. https://doi.org/10.1038/s41598-025-95380-5
7. Jung YH, Jang H, Park S, et al. Effectiveness of Personalized Hippocampal Network-Targeted Stimulation in Alzheimer Disease: A Randomized Clinical Trial. JAMA Network Open. 2024;7(5):e249220. https://doi.org/10.1001/jamanetworkopen.2024.9220
8. Koch G, Bonnì S, Pellicciari MC, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain. 2022;145(11):3776-3786. https://doi.org/10.1093/brain/awac285
9. Koch G, Casula EP, Bonnì S, et al. Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial. Alzheimer's Research & Therapy. 2025;17(1):69. https://doi.org/10.1186/s13195-025-01709-7
10. Kuo PH, Chen AY-C, Rodriguez RJ, et al. Transcranial Magnetic Stimulation for the Treatment of Chemo Brain. Sensors. 2023;23(19):8017. https://doi.org/10.3390/s23198017
11. Nilakantan AS, Mesulam M-M, Weintraub S, et al. Network-targeted stimulation engages neurobehavioral hallmarks of age-related memory decline. Neurology. 2019;92(20):e2349-e2354. https://doi.org/10.1212/WNL.0000000000007502
12. Padala PR, Padala KP, Lensing SY, et al. Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment. Psychiatry Research. 2018;261:312-318. https://doi.org/10.1016/j.psychres.2017.12.063
13. Pagali SR, Kumar R, LeMahieu AM, et al. Efficacy and safety of transcranial magnetic stimulation on cognition in mild cognitive impairment, Alzheimer disease, Alzheimer's disease-related dementias, and other cognitive disorders: A systematic review and meta-analysis. International Psychogeriatrics. 2024;36(10):880-928. https://pubmed.ncbi.nlm.nih.gov/38329083/
14. Sabbagh MN, Sadowsky C, Tousi B, et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. Alzheimer's & Dementia. 2020;16(4):641-650. https://doi.org/10.1016/j.jalz.2019.08.197
15. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239
16. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. Journal of Neuroscience. 2001;21(15):RC157. https://doi.org/10.1523/JNEUROSCI.21-15-j0003.2001
17. Thomson AC, Kenis G, Tielens S, et al. Transcranial Magnetic Stimulation-Induced Plasticity Mechanisms: TMS-Related Gene Expression and Morphology Changes in a Human Neuron-Like Cell Model. Frontiers in Molecular Neuroscience. 2020;13:528396. https://doi.org/10.3389/fnmol.2020.528396
18. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388(1):9-21. https://doi.org/10.1056/NEJMoa2212948
19. Wang JX, Rogers LM, Gross EZ, et al. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science. 2014;345(6200):1054-1057. https://doi.org/10.1126/science.1252900
20. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA: A Cancer Journal for Clinicians.2011. https://pubmed.ncbi.nlm.nih.gov/21826010/
21. Wu X, Ji GJ, Geng Z, et al. Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: a randomized controlled trial. Brain Stimulation. 2022;15(1):35-45. https://doi.org/10.1016/j.brs.2021.11.007

Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. TMS for cognitive decline is currently used off-label. Individual results may vary. Always consult with a qualified healthcare provider about your specific situation.